Sclerosis, a progressive neurodegenerative disease with selective loss of anterior horn cells. Lithium is known to enhance the potency of transplanted cells, while being well tolerated by ALS patients. Additionally, rehabilitation significantly improves outcomes in various neurodegenerative disorders. We present a 47-year-old male patient suffering from ALS for 2 years, whose treatment involved intrathecal transplantation of autologous Bone Marrow-Derived Mononuclear Cells and long-term Lithium, followed by multidisciplinary neurorehabilitation, and standard Riluzole treatment. ALSFRSr score improved from 39 to 41; FIM remained stable at 101; 6MWT distance improved from 396 m to 480 m and Berg Balance score remained stable at 56 over a span of 18 months. Symptomatic improvements were seen in speech, swallow, stamina, walking and muscle strength; fasciculations and cramps reduced drastically. The highlight of this case is the maintenance of the patient's condition in view of a degenerative prognosis. Cellular therapy along with long-term Lithium and holistic rehabilitation, in addition to standard Riluzole treatment-together termed as Neuroregenerative Rehabilitation Therapy-is a novel approach for halting disease progression and qualitatively improving living conditions, for ALS patients and caregivers alike.
Introduction
Amyotrophic Lateral Sclerosis (ALS) is an idiopathic, relentless neurodegenerative disorder with selective degeneration of anterior horn motor neurons 1 . Clinically, it is characterized by wasted, fasciculating musculature leading to progressive respiratory insufficiency. Prognosis varies depending on age of symptom onset and type of ALS 2 . An exact incidence is unknown 3 , but has steadily increased globally over the past few decades 4 . Diagnosis is confirmed based on thorough neurological and electrophysiological investigation 5 .
Standard care for ALS has barely evolved over the years; other than Riluzole administration 6 , it involves palliative management at best. Only recently, Nuedexta 7 (symptomatic treatment of pseudobulbar affect) and Edaravone (solely effective in the early stages 8 ) have been approved by the Food and Drug Administration of the United States (USFDA) for treatment of ALS in the USA. Given the multivariate pathophysiology of this disease, including the involvement of misfolded ubiquitinated aggregates 9 , excessive free radicals 10 , excitotoxicity 11 , etc., ALS treatment demands a comprehensive approach, going beyond palliative care. Effective therapies for halting disease progression and improving quality of life are the need of the hour. Various studies worldwide advocate the efficacy and safety of autologous bone marrow-derived mononuclear cells (autologous BMMNCs) as a therapeutic intervention for neurological disorders [12] [13] [14] , including for ALS [15] [16] [17] . Lithium not only increases the survival and potency of these transplanted cells 18 , but is also safe when administered to ALS patients 19, 20 . Holistic rehabilitation bolsters the tendency of these cells to integrate into target tissue 21 . We present a case of a 47-year-old male with ALS, who underwent an intrathecal autologous BMMNCs transplantation in conjunction with long-term Lithium and standard Riluzole treatment, followed by customized, multidisciplinary rehabilitation to improve the musculoskeletal sequelae of transplantation-such as physical, occupational and speech therapy, and psychological counseling-together termed as
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Neuroregenerative Rehabilitation Therapy (NRRT). 23 . The patient was given local anesthesia in the region of anterior superior iliac spine; 110 ml of bone marrow was aspirated using a bone marrow aspiration needle, collected in heparinized tubes, and transferred aseptically to the stem cell laboratory.
Case Presentation

Separation of BMMNCs
Separation of BMMNCs was achieved by differential centrifugation under aseptic conditions as described previously 24 . Briefly, bone marrow was diluted in the ratio of 1:1 with normal saline. The diluted bone marrow was subjected to density gradient separation using Ficoll-Paque media, by centrifuging it at 440 g for 35 minutes in a swinging bucket rotor without brake at 20°C. BMMNCs were obtained as a buffy coat. The BMMNCs were washed thrice with normal saline, by centrifuging at 300 g for 15 minutes in a swinging bucket rotor without brake at 20°C, and finally resuspended in 1 ml of normal saline. Viable count of the isolated BMMNCs was done using Trypan blue vital dye, which is mixed in 1:1 proportion and loaded on to the haemocytometer, for the total cell count and viable count. 8.8×10 7 BMMNCs were obtained at a viability rate of 98%.
This was further confirmed by TALI cell counter. CD34 + analysis was done using Fluorescence Activated Cell Sorting (FACS) using CD34 PE antibody, and was found to be 6.36%. brachii and brachioradialis. 1 gm methyl prednisolone in 500 ml Ringer's Lactate (RL) solution was simultaneously injected intravenously, to reduce local inflammatory response and improve stem cell survival 25 . The patient was then closely monitored for any immediate adverse events during his stay at the hospital.
Administration of BMMNCs
Neurorehabilitation Therapy
The principal emphasis of physical rehabilitation is on strengthening muscles without fatigue, improving transitions, and improving endurance as well as respiratory capacity. The patient had difficulty performing certain activities of daily living (ADL), such as bathing, dressing, toilet hygiene, feeding and eating, and sitting in bed. Thus, he was administered occupational therapy to improve vital capacity, trunk mobility, posture, and sitting balance. Since the patient's primary complaint was reduction of upper limb function, strengthening activities for upper limbs along with functional and purposeful activities for improving gross and fine motor skills were prescribed to him. Speech therapy was performed to improve oromotor function, such as proprioceptive neuromuscular facilitation (PNF) exercises. Psychological and family counseling was also performed to help the patient and his family to cope with the difficult diagnosis of ALS. Post discharge, he was put on a home exercise program for 6 months to enhance the effectiveness of autologous BMMNC transplantation. He was prescribed 50 mg Riluzole twice a day. 300 mg Lithium was also prescribed once a day, and serum Lithium levels were maintained at 0.5 to 0.8 mmol/L. Based on improvements seen after the first transplant, a repeat intrathecal autologous BMMNC treatment was administered 8 months later, and a total of 2.08×10 8 BMMNCs with a cell viability of 98% were injected. We did not perform an intramuscular transplantation of autologous BMMNCs at this time, because there were no significant improvements seen in the individual muscles via Manual Muscle Testing (MMT). At the time of this transplantation, the CD34 + fraction was 6.48%.
This was followed again by a comprehensive neurorehabilitative routine, both as described above.
Results and Discussion
3 months following the 1 st autologous BMMNC transplantation, the patient's ALS-FRSr Score improved by 2 points. Choking episodes reduced. Before the first transplant, he had slight dyspnoea after walking less than a kilometer; however, 3 months after the first transplant, he reported being easily able to walk 1-2 km without any shortness of breath. Abdominal cramps stopped completely. Good voluntary control was evident by a bilateral increase in the muscle strength of neck rotators, which was maintained 18 months later as well. He showed stability in his functional activities and reported an increase in his stamina and balance; he could perform exercises and activities for longer durations of time, especially lower limb exercises. This observation dovetailed with a corresponding increase in his 6MWT distance from 396 m to 501.6 m after three months. No episodes of falls were noted in this period. Static and dynamic sitting as well as standing balance showed improvement, and walking balance was maintained. His left and right reach increased; bed mobility also improved. However, left upper limb fasciculations had increased. 8 months post first transplantation, ALS-FRSr score was maintained and improved oromotor functions were evident. Choking stopped completely, and neck pain reduced. Speech intelligibility score improved to 1 from 2 at pre-assessment. But, fasciculations had increased in both lower limbs. At this point in time, given the improvements in his condition, the patient underwent a 2 nd autologous BMMNC transplantation. 34 in healthy subjects aged 50 to 85 years, measured in meters (m). The patient also gave a history of walking over 600 m daily when he was asymptomatic. These outcome measures clearly demonstrate that the patient's condition has remained stable over time. . We chose to work with BMMNCs given their safety and ethical approval. Neuroregenerative Rehabilitation Therapy along with longterm Lithium is an effective, novel, multi-pronged therapeutic approach for the treatment of ALS. We have, in the past, published a study which showed that the survival duration of ALS patients, who underwent intrathecal transplantation of autologous BMMNCs, followed by 6 weeks of Lithium post intervention, was higher by 30 38 . They show that the median time taken to achieve 4-point deterioration on the ALSFRSr scale was 16.7 months. In the case of this patient, not only did the ALSFRSr score increase by 2 points in a span of 6 months post intervention, but his condition also stabilized. A study conducted by Sanjak et al. 39 shows that in healthy subjects aged 50 to 85 years, the mean walking distance reported during 6MWT ranged from 576 m to 631 m (median distance = 603.5 m; see Asymptomatic 6MWT data point in Figure 1 ). significantly greater distance (418.7 ± 125 m) than ambulatory ALS patients with assistive devices, i.e. patients who had progressed in the disease (218.9 ± 108 m), thus correlating the 6MWT with disease progression in ALS. Here, the patient's 6MWT distance increased from 396 m at assessment to 480 m over 18 months. Another study by De Groot et al. 40 demonstrates that FIM correlates with the ALSFRS values in the different stages of ALS; in this case, the patient's FIM score remained constant at 101 over the course of 18 months. This is a remarkable improvement, given the degenerating prognosis of ALS. The 2-point increase in ALSFRSr scale from 39/48 to 41/48, the stable FIM score (unchanged at 101/126), the increase in the 6MWT from 396 m to 480 m and the maintenance of the Berg Balance Scale at 56/56, for a stretch of 18 months, implies that the disease progression has been mitigated, in contrast to the stark natural deteriorating prognosis of ALS. Qualitatively, the patient also noted improvements in his temperament. The maintenance of the patient's condition over such an extended period of time may be attributed to the benefits of autologous BMMNC administration along with long term Lithium, rehabilitation, and standard pharmacological treatment.
The directed administration of adult autologous cells intrathecally may enhance the arsenal of neuroprotective cells that are capable of differentiation and subsequent integration into target tissue 17 . Being autologous, these cells are a safe treatment modality; and, because these are adult stem cells, they are not prone to developing tumorigenic attributes.
Multiple clinical trials, in a variety of neurological ailments, have demonstrated the safety and efficacy of adult autologous BMMNCs as a therapy [12] [13] [14] 41 . None of the studies have shown any major or irreversible adverse events post transplantation. BMMNCs have been known to confer neuroprotection through various paracrine and somatic mechanisms. These cells secrete and regulate a plethora of neurotrophic factors, like ciliary neurotrophic factor (CNTF) and brain-derived neurotrophic factor (BDNF) 42 , glial cell-derived neurotrophic factor (GDNF) 43 , β-nerve growth factor (β-NGF) 44 , vascular endothelial growth factor (VEGF) 45 , tumor necrosis factor (TNF)-α and interleukins (IL-1α, IL-β, IL-6, IL-10) 46 , granulocyte-colony stimulating factor (G-CSF) 47 , granulocyte macrophage-colony stimulating factor (GM-CSF) 44 , basic fibroblast growth factor (bFGF) 45 , platelet-derived growth factor-BB (PDGF-BB) 44 and angiopoietin 1 (ANG-1) 48 53 , suggesting that the potential neuroprotective activity of Lithium in the above clinical trials may have been masked by Riluzole. We postulate that long-term Lithium administration, along with intrathecal transplantation of autologous BMMNCs, may be the key to the steady maintenance of the patient's condition. Previously, we have published a case report of a 40-year-old female diagnosed with ALS, who showed functional and neurological improvements on ALSFRSr and FIM scales over a period of 17 months post intrathecal transplantation of autologous BMMNCs, 6 weeks of Lithium and intensive neurorehabilitiation 54 . In this case, the patient showed better outcomes; these extended benefits may be attributed to longterm Lithium administration. It is a well-established fact that Lithium increases the survival, potency and target tissue integration of BMMNCs 18 , in addition to conferring neuroprotection in vitro 55 and in vivo 56 in the context of ALS. Hashimoto et al. 55 show that treatment of rodent cortical neurons in vitro with Lithium increased cellular BDNF in 3 days. BDNF plays a critical, multifaceted role in the nervous system 57 . In 5 days, the authors observed increased phosphorylation of Tyrosine receptor kinase B (TrkB-a BDNF growth factor receptor), suggesting that long-term Lithium administration enhances BDNF expression/secretion, leading to the activation of TrkB receptor. In an in vivo study, transgenic ALS mice treated with Lithium showed improved survival compared with wild-type mice treated with saline 56 . In a pilot study examining the effect of Lithium treatment in patients with ALS, a significant increase was seen in the Lithium plus Riluzole cohort compared with the Riluzole only cohort 56 . This clinical study reported a difference in survival at 15 months; 100% survival was observed in the Lithium plus Riluzole cohort, compared with 70% in the Riluzole only cohort. Taken together, these results suggest that long term Lithium may have played a pronounced, consequential role in the outcome of this patient. for our patient. Studies suggest that exercise leads to enhanced cell signaling, mobilizing stem cells into circulation, with some evidence of myocardial regeneration in patients 21 . The aim of rehabilitation was to maximize functionality, increase strength and flexibility, improve balance and coordination, and prevent fasciculations. In addition to the above, our patient was prescribed a standard Riluzole treatment at a dose of 100 mg/day as standard therapy to reduce the neurotoxic effects of excessive extracellular glutamate in the neuronal microenvironment.
Limitations
This report summarizes the totality of treatments administered to the patient. Although beneficial effects have been reported, the individual contributions of various treatment modalities could not be assessed independently. These findings must be confirmed via larger clinical trials for widespread acceptance and standardization. Another limitation is that a genetic test was not performed in this patient.
Conclusion
This case report demonstrates stabilization of a male ALS patient's condition via Neuroregenerative Rehabilitation Therapy along with long-term Lithium and Riluzole. Autologous BMMNC transplantation augmented by long term Lithium is a safe, effective therapy for ALS. This combinatorial treatment when administered in conjunction with a structured, personalized neurorehabilitative program and standard Riluzole prescription, is a novel, holistic therapeutic modality for the treatment of ALS and may have positive effects on survival duration as well as the quality of life of patients and caregivers faced with this devastating disease. The challenge for the future is to design controlled clinical studies-with large sample sizes-that standardize this therapeutic regime in attenuating disease progression in ALS.
